Robotic Surgery and Automation in Surgical Procedures

Robotic surgery is no longer something hospitals showcase as a premium differentiator—it is steadily becoming part of the everyday infrastructure of modern healthcare. What began as a cutting-edge capability confined to elite academic hospitals is now spreading across high-volume regional hospitals and, increasingly, ambulatory surgery centers (ASCs). This shift reflects a broader change in how health systems think about surgical care: robotics is moving from “nice to have” to “hard to operate without.”

The numbers tell part of the story. According to Mordor Intelligence, the global surgical robotics market is valued at approximately US$8.31 billion in 2025 and is expected to grow to US$12.83 billion by 2030, representing a compound annual growth rate (CAGR) of just over 9%. Behind this growth is a powerful mix of demographic pressure, economic restructuring within healthcare systems, and rapid technological evolution that is reshaping how surgery is delivered worldwide.

Why robotics is scaling now
At a macro level, aging populations are driving a steady increase in surgical volumes—especially in orthopedics, urology, and general surgery. These are precisely the areas where consistency, precision, and repeatability matter most. Surgeons are increasingly expected to deliver predictable outcomes across growing caseloads, and robotic assistance offers a way to standardize complex procedures while reducing variability.

At the same time, hospital consolidation is changing purchasing behavior. In the United States and across parts of Asia, large hospital networks are replacing fragmented systems. These organizations favor standardized platforms that can be rolled out across multiple facilities, supported by centralized training and shared service contracts. Robotics fits neatly into this model, particularly when systems are deployed at scale rather than confined to individual departments.

Reimbursement trends are also helping remove barriers to adoption. Expanding coverage—most notably in the U.S. and China—has reduced the friction that once made robotic procedures feel discretionary. As payers increasingly recognize robotic-assisted approaches within established procedural codes, robotics is moving into routine clinical pathways rather than being reserved for select cases.

From machines to ecosystems
One of the most important shifts underway is how surgical robots are being positioned. They are no longer viewed simply as expensive pieces of hardware. Instead, vendors are increasingly framing them as integrated robot-plus-software ecosystems. In this model, the real differentiation comes from software layers—artificial intelligence (AI), data analytics, and workflow optimization—rather than mechanical performance alone.

AI-enabled modules are already expanding robotic surgery into soft-tissue, neurosurgical, and cardiac applications. At the same time, smaller and more modular system designs are making robotics viable in outpatient and ambulatory environments, where space, staffing, and turnover times matter as much as technical capability.

Despite these advances, the market remains highly concentrated. Established players continue to benefit from large installed bases, deep surgeon familiarity, and long-term service contracts that are difficult for new entrants to displace. In practice, this means that while innovation is accelerating, competitive disruption remains gradual rather than sudden.

What is driving demand in 2025 and beyond
Several demand drivers are reinforcing one another. Aging demographics and rising procedure volumes remain foundational, particularly in joint replacement. Orthopedic surgeons, in particular, value robotic systems for their ability to improve alignment accuracy and procedural consistency—factors that directly influence long-term patient outcomes.

Training dynamics also play an increasingly important role. Hospitals face ongoing challenges in maintaining consistent surgical quality across teams with varying experience levels. Robotic platforms that shorten learning curves and standardize complex steps are becoming attractive not just clinically, but operationally.

Hospital consolidation further strengthens the economic case. Large health systems can justify robotics by spreading utilization across multiple specialties and service lines, improving return on investment (ROI). Instead of asking whether a single department can support a robotic system, executives are now evaluating platforms at the enterprise level.

Reimbursement momentum continues to build. Payers are refining policies to better reflect technology-enabled surgical workflows, including robotic assistance. This trend is expected to continue into 2026, with further expansion of robotics-inclusive coding—most notably the introduction of a Category III code effective January 1, 2026, for robotic lymphatic surgery.

Meanwhile, the shift toward outpatient care is accelerating. As systems become more compact and workflows more efficient, ASCs are emerging as one of the fastest-growing user segments, a trend Mordor Intelligence projects will persist through 2030.




Who is leading the technology race?
In soft-tissue, multiport robotics—covering general surgery, urology, and gynecology—Intuitive Surgical remains the clear leader in 2025. Its da Vinci ecosystem benefits from unmatched scale, deep surgeon training infrastructure, and continuous platform upgrades. A GlobalData analyst estimates that Intuitive held around 60% of the global market in 2024. With more than 10,000 da Vinci systems installed worldwide as of mid-2025, the company’s installed base continues to underpin recurring revenue and long-term customer lock-in.

Medtronic has emerged as the most credible challenger at scale. Following FDA clearance in December 2025 for Hugo RAS in urologic procedures, the company is beginning to build momentum in the U.S., supported by extensive international experience. Tens of thousands of Hugo procedures performed across more than 30 countries have generated valuable clinical and operational data ahead of broader rollout.

Johnson & Johnson MedTech represents the next wave of competition. Its OTTAVA system completed its first clinical study cases in April 2025 after IDE approval late the previous year. Meanwhile, CMR Surgical stands out as a strong independent challenger. Its Versius system received FDA marketing authorization in October 2024 and is being positioned as a modular, portable alternative for mid-tier hospitals.

Orthopedic robotics follows a different competitive logic, with greater emphasis on implant alignment, haptics, and CT-based planning. Stryker’s Mako platform remains the most established franchise, having surpassed one million total knee procedures globally. Zimmer Biomet continues to expand its ROSA Knee platform, including FDA clearance in 2025 for ROSA Knee with OptimiZe. In spine and navigation robotics, Globus Medical and Medtronic are competing on integrated navigation ecosystems rather than robotic arms alone.

China’s rapid rise
China is one of the fastest-scaling robotic surgery markets globally. Adoption is accelerating alongside the development of domestic platforms. A 2025 editorial in the Asian Journal of Urology reported that more than 400 robotic surgical platforms were installed nationwide by the end of 2024. While international systems dominated early adoption, local manufacturers are increasingly competitive, supported by national industrial policy, cost sensitivity, and procurement preferences that favor domestic suppliers.

Looking ahead to 2026
By 2026, robotic surgery is expected to enter a more mature, value-driven phase. The next competitive battleground will be software-defined surgery. Vendors are racing to deploy AI-driven capabilities such as intraoperative guidance, anatomy recognition, automated camera control, and workflow analytics. Early demonstrations of AI-guided camera autonomy point toward near-term automation that reduces staffing pressure and improves visualization—rather than replacing surgeons.

Task-level automation will also expand. Automated camera movement, suturing assistance, safety constraints, and instrument tracking are likely to become standard features as sensing and computing power improve. At the same time, pricing power is expected to shift toward healthcare providers as competition intensifies, leading to bundled offerings, outcome-linked contracts, and greater scrutiny of total cost of ownership.

Across regions, evidence standards are rising. Hospitals and payers increasingly expect proof of ROI, improved outcomes, and reduced surgeon workload. As a result, the market is moving beyond adoption driven by novelty and toward adoption driven by measurable, system-wide value.